681 related articles for article (PubMed ID: 34453074)
21. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
22. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
23. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
Špacir Prskalo Z; Bulić P; Langer S; Gaće M; Puljiz M; Danolić D; Alvir I; Mamić I; Šušnjar L; Mayer L
J Obstet Gynaecol; 2019 Feb; 39(2):195-201. PubMed ID: 30207507
[TBL] [Abstract][Full Text] [Related]
24. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
25. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
[TBL] [Abstract][Full Text] [Related]
26. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer.
Lee SS; Park JS; Lee KB; Jeong DH; Byun JM; Lee SM
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1123-1127. PubMed ID: 33906304
[TBL] [Abstract][Full Text] [Related]
29. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
30. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.
Yang J; Sa M; Huang M; Yang J; Xiang Z; Liu B; Tang A
Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857
[TBL] [Abstract][Full Text] [Related]
31. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
[TBL] [Abstract][Full Text] [Related]
33. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
34. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
35. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
37. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
38. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
39. Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
Chudecka-Głaz A; Cymbaluk-Płoska A; Jastrzębska J; Menkiszak J
Tumour Biol; 2016 Jul; 37(7):8879-87. PubMed ID: 26753953
[TBL] [Abstract][Full Text] [Related]
40. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
